{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:30:38Z","timestamp":1792096238283,"version":"4.4.0"},"reference-count":203,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.clinthera.2017.07.001","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:16:00Z","timestamp":1501028160000},"page":"1519-1536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Progress and Works in Progress: Update on Flavivirus Vaccine Development"],"prefix":"10.1016","volume":"39","author":[{"given":"Matthew H.","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.07.001_bib1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0140-6736(08)60238-X","article-title":"Pathogenic flaviviruses","volume":"371","author":"Gould","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.07.001_bib2","unstructured":"PAHO WHO | Regional Zika Epidemiological Update (Americas) March 10, 2017. http:\/\/www2.paho.org\/hq\/index.php?option=com_content&view=article&id=11599&Itemid=41691&lang=en. Accessed April 17, 2017."},{"key":"10.1016\/j.clinthera.2017.07.001_bib3","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1128\/JVI.00252-16","article-title":"Zika virus: new clinical syndromes and its emergence in the western hemisphere","volume":"90","author":"Lazear","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(16)30513-8","article-title":"Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015\u201316: a modelling study","volume":"17","author":"Kraemer","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMp1702172","article-title":"Yellow fever - once again on the radar screen in the Americas","volume":"376","author":"Paules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.07.001_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","article-title":"Designing tomorrow\u2019s vaccines","volume":"368","author":"Nabel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0264-410X(02)00564-9","article-title":"New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund","volume":"21","author":"Martin","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMe1509442","article-title":"A Candidate dengue vaccine walks a tightrope","volume":"373","author":"Simmons","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib12","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1056\/NEJMp1609300","article-title":"Fast-track zika vaccine development \u2014 is it possible?","volume":"375","author":"Thomas","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CMR.00072-15","article-title":"Zika virus","volume":"29","author":"Musso","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2017.07.001_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.chom.2009.04.001","article-title":"Pathogenesis of flavivirus infections: using and abusing the host cell","volume":"5","author":"Fernandez-Garcia","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clinthera.2017.07.001_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature17994","article-title":"Structure of the thermally stable Zika virus","volume":"533","author":"Kostyuchenko","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.07.001_bib16","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3390\/v3122374","article-title":"The human antibody response to dengue virus infection","volume":"3","author":"Wahala","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.clinthera.2017.07.001_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.mayocp.2016.02.017","article-title":"Zika virus in the Americas: a review for clinicians","volume":"91","author":"Sampathkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2017.07.001_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrmicro.2016.125","article-title":"Zika virus - reigniting the TORCH","volume":"14","author":"Coyne","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib20","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects \u2014 reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/jamaneurol.2016.3720","article-title":"Congenital Zika virus infection","volume":"73","author":"Melo","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2105\/AJPH.2016.303115","article-title":"Initial description of the presumed congenital Zika syndrome","volume":"106","author":"Miranda-Filho","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.clinthera.2017.07.001_bib23","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.07.001_bib24","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMc1609015","article-title":"Zika virus and the Guillain\u2013Barr\u00e9 syndrome \u2014 case series from seven countries","volume":"375","author":"dos Santos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jamaneurol.2016.1268","article-title":"Anticipating the challenges of Zika virus and the incidence of Guillain-Barr\u00e9 syndrome","volume":"73","author":"Gold","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib26","doi-asserted-by":"crossref","first-page":"i6157","DOI":"10.1136\/bmj.i6157","article-title":"Babies with microcephaly in Brazil are struggling to access care","volume":"355","author":"Collucci","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2017.07.001_bib27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1473-3099(16)30270-5","article-title":"Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study","volume":"16","author":"Bogoch","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.07.001_bib29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1289\/EHP218","article-title":"An analysis of the potential impact of climate change on dengue transmission in the Southeastern United States","volume":"125","author":"Butterworth","year":"2017","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.clinthera.2017.07.001_bib30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.4269\/ajtmh.14-0151","article-title":"First case of Zika virus infection in a returning Canadian rraveler","volume":"91","author":"Fonseca","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib31","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.15585\/mmwr.mm6538e1","article-title":"Local mosquito-borne transmission of Zika virus \u2014 Miami-Dade and Broward Counties, Florida, June\u2013August 2016","volume":"65","author":"Likos","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2017.07.001_bib32","doi-asserted-by":"crossref","first-page":"taw059","DOI":"10.1093\/jtm\/taw059","article-title":"Estimated global exportations of Zika virus infections via travellers from Brazil from 2014 to 2015","volume":"23","author":"Quam","year":"2016","journal-title":"J Travel Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1179\/2047773214Y.0000000163","article-title":"Dengue and chikungunya: long-distance spread and outbreaks in na\u00efve areas","volume":"108","author":"Rezza","year":"2014","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.clinthera.2017.07.001_bib34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4269\/ajtmh.15-0128","article-title":"Post outbreak review: dengue preparedness and response in Key West, Florida","volume":"93","author":"Hayden","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.15585\/mmwr.mm6514a3","article-title":"Male-to-Male sexual transmission of Zika virus - Texas, January 2016","volume":"65","author":"Deckard","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2017.07.001_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmi.2016.12.027","article-title":"Sexually acquired Zika virus: a systematic review","volume":"23","author":"Moreira","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2017.07.001_bib37","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S1473-3099(16)30193-1","article-title":"Zika virus in the female genital tract","volume":"16","author":"Prisant","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib38","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3201\/eid1705.101939","article-title":"Probable non-vector-borne transmission of Zika virus, Colorado, USA","volume":"17","author":"Foy","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ajt.14083","article-title":"Zika virus in transplantation: emerging infection and opportunities","volume":"17","author":"Blumberg","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2017.07.001_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5858\/arpa.2016-0430-RA","article-title":"Zika and the blood supply: a work in progress","volume":"141","author":"Katz","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMc1607262","article-title":"Evidence for transmission of Zika virus by platelet transfusion","volume":"375","author":"Motta","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib42","unstructured":"Global strategy to eliminate yellow fever epidemics. http:\/\/www.who.int\/immunization\/sage\/meetings\/2016.october\/2_EYE_Strategy.pdf?.ua=1. Accessed June 14, 2017."},{"key":"10.1016\/j.clinthera.2017.07.001_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.1997.0056","article-title":"Yellow Fever Vaccines","volume":"25","author":"Barrett","year":"1997","journal-title":"Biologicals"},{"key":"10.1016\/j.clinthera.2017.07.001_bib44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4269\/ajtmh.1928.s1-8.103","article-title":"Experimental transmission of yellow fever to laboratory animals","volume":"1","author":"Stokes","year":"1928","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib46","year":"2016","journal-title":"Amendment to International Health Regulations (2005), Annex 7 (yellow fever)"},{"key":"10.1016\/j.clinthera.2017.07.001_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4269\/ajtmh.2005.72.339","article-title":"Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial","volume":"72","author":"Pfister","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib48","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.84.7.2019","article-title":"Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it","volume":"84","author":"Hahn","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2017.07.001_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0168-1702(94)00076-O","article-title":"Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213","volume":"35","author":"dos Santos","year":"1995","journal-title":"Virus Res"},{"key":"10.1016\/j.clinthera.2017.07.001_bib50","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1093\/cid\/civ603","article-title":"Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali","volume":"61","author":"Roy Chowdhury","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib52","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0264-410X(02)00811-3","article-title":"Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up","volume":"21","author":"Haglund","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib53","first-page":"717","article-title":"Tick-borne encephalitis in Europe and beyond--the epidemiological situation as of 2007","volume":"13","author":"Suss","year":"2008","journal-title":"Euro Surveill Bull Eur sur les Mal Transm Eur Commun Dis Bull"},{"key":"10.1016\/j.clinthera.2017.07.001_bib54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ttbdis.2010.10.007","article-title":"Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview","volume":"2","author":"Suss","year":"2011","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib55","doi-asserted-by":"crossref","first-page":"737v747","DOI":"10.1586\/14760584.2015.985661","article-title":"Review of tick-borne encephalitis and vaccines: clinical and economical aspects","volume":"14","author":"Smit","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.clinthera.2017.07.001_bib56","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1016\/j.vaccine.2011.07.024","article-title":"Vaccines against tick-borne encephalitis: WHO position paper - recommendations","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib57","article-title":"Vaccines for preventing tick\u2010borne encephalitis","volume":"1","author":"Demicheli","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.07.001_bib58","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3201\/eid2101.141227","article-title":"Kyasanur Forest disease outbreak and vaccination strategy, Shimoga District, India, 2013\u20132014","volume":"21","author":"Kiran","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib60","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1016\/j.vaccine.2007.08.024","article-title":"Field effectiveness of vaccination against tick-borne encephalitis","volume":"25","author":"Heinz","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2310\/7060.2005.12205","article-title":"Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers","volume":"12","author":"Zent","year":"2005","journal-title":"J Travel Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib62","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2006.03.061","article-title":"Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies","volume":"24","author":"Loew-Baselli","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib63","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1016\/j.vaccine.2009.09.069","article-title":"Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs","volume":"27","author":"Stiasny","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib64","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1128\/JVI.00660-09","article-title":"Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E","volume":"83","author":"Kiermayr","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib65","series-title":"Background document on vaccines and vaccination against tick\u2013borne encephalitis","author":"Kollaritsch","year":"2011"},{"key":"10.1016\/j.clinthera.2017.07.001_bib66","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.vaccine.2014.01.072","article-title":"Irregular tick-borne encephalitis vaccination schedules: the effect of a single catch-up vaccination with FSME-IMMUN. A prospective non-interventional study","volume":"32","author":"Schosser","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib67","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1586\/erv.12.86","article-title":"Vaccines and vaccination against tick-borne encephalitis","volume":"11","author":"Kollaritsch","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.clinthera.2017.07.001_bib68","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Heal Organ"},{"key":"10.1016\/j.clinthera.2017.07.001_bib69","first-page":"230","article-title":"Evaluation of Japanese B encephalitis vaccine, III: Okayama field trial, 1946-1949","volume":"63","author":"Ando","year":"1956","journal-title":"Am J Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib70","first-page":"238","article-title":"Evaluation of Japanese B encephalitis vaccine, IV: pattern of serologie response to vaccination over a five-year period in an endemic area (Okayama, Japan)","volume":"63","author":"Tigertt","year":"1956","journal-title":"Am J Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib71","first-page":"1","article-title":"Japanese encephalitis vaccines: immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease","author":"Hegde","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clinthera.2017.07.001_bib72","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1016\/j.vaccine.2007.05.034","article-title":"WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006","volume":"25","author":"Ferguson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib73","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1016\/j.vaccine.2010.02.105","article-title":"Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities","volume":"28","author":"Yu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib74","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib75","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib76","year":"2014","journal-title":"Background paper on Japanese encephalitis vaccines"},{"key":"10.1016\/j.clinthera.2017.07.001_bib77","doi-asserted-by":"crossref","first-page":"jiw533","DOI":"10.1093\/infdis\/jiw533","article-title":"Persistence of wild-type Japanese encephalitis virus strains cross-neutralization five years following JE-CV immunization","volume":"215","author":"Feroldi","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib78","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s13312-013-0292-9","article-title":"Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization","volume":"50","author":"Vashishtha","year":"2013","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.clinthera.2017.07.001_bib79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0264-410X(00)00039-6","article-title":"Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus","volume":"18","author":"Tsarev","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib80","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4269\/ajtmh.2001.65.242","article-title":"Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent","volume":"65","author":"Uchil","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib81","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in na?ve and dengue exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib82","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clinthera.2017.07.001_bib83","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/1471-2334-14-391","article-title":"Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline","volume":"14","author":"Campi-Azevedo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib84","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.16-0401","article-title":"A meta-analysis of serological response associated with yellow fever vaccination","volume":"95","author":"Jean","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15585\/mmwr.mm6604a6","article-title":"Notes from the field: knowledge, attitudes, and practices regarding yellow fever vaccination among men during an outbreak \u2014 Luanda, Angola, 2016","volume":"66","author":"Marlow","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2017.07.001_bib86","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.16.031016","article-title":"Reining in Angola\u2019s yellow fever outbreak","volume":"94","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.clinthera.2017.07.001_bib87","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow fever in Angola and beyond \u2014 the problem of vaccine supply and demand","volume":"375","author":"Barrett","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib88","doi-asserted-by":"crossref","unstructured":"Hotez PJ, Singh S, Zhou X, et al. Vaccine diplomacy: historical perspectives and future directions. Lustigman S, ed. PLoS Negl Trop Dis. 2014;8:e2808.","DOI":"10.1371\/journal.pntd.0002808"},{"key":"10.1016\/j.clinthera.2017.07.001_bib89","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.326.7394.865","article-title":"West Nile encephalitis","volume":"326","author":"Solomon","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2017.07.001_bib90","first-page":"221","article-title":"Equine vaccine for West Nile virus","volume":"114","author":"Ng","year":"2003","journal-title":"Dev Biol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vetimm.2008.02.002","article-title":"A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse","volume":"123","author":"El Garch","year":"2008","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib92","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1016\/j.vaccine.2010.06.045","article-title":"Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations","volume":"28","author":"Schlick","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib93","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.4269\/ajtmh.2010.09-0310","article-title":"Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection","volume":"82","author":"Widman","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib94","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.vaccine.2009.10.112","article-title":"Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus","volume":"28","author":"Whiteman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib95","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib97","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.4049\/jimmunol.167.9.5273","article-title":"Immunization of mice against West Nile virus with recombinant envelope protein","volume":"167","author":"Wang","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib98","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.vaccine.2013.12.030","article-title":"Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice","volume":"32","author":"Magnusson","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib99","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.vaccine.2005.03.006","article-title":"A recombinant envelope protein vaccine against West Nile virus","volume":"23","author":"Ledizet","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib100","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.vaccine.2006.08.018","article-title":"Preparation and immunogenic properties of a recombinant West Nile subunit vaccine","volume":"25","author":"Lieberman","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib101","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib102","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.vaccine.2006.08.008","article-title":"Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis","volume":"25","author":"Watts","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib103","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/fmb.14.67","article-title":"Technologies for the development of West Nile virus vaccines","volume":"9","author":"Ulbert","year":"2014","journal-title":"Futur Microbiol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib104","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib105","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1016\/j.vaccine.2011.04.116","article-title":"A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII","volume":"29","author":"Schneeweiss","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib106","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/jiu481","article-title":"Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort","volume":"211","author":"Corbett","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib107","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clinthera.2017.07.001_bib108","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/infdis\/jir607","article-title":"B-cell responses during primary and secondary dengue virus infections in humans","volume":"204","author":"Mathew","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib109","first-page":"4","article-title":"Pathogenesis of dengue: dawn of a new era","author":"Halstead","year":"2015","journal-title":"F1000Research"},{"key":"10.1016\/j.clinthera.2017.07.001_bib110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4269\/ajtmh.16-0222","article-title":"Licensed dengue vaccine: public health conundrum and scientific challenge","volume":"95","author":"Halstead","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib111","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.07.001_bib112","doi-asserted-by":"crossref","first-page":"14606","DOI":"10.1128\/JVI.79.23.14606-14613.2005","article-title":"Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus","volume":"79","author":"Gould","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib113","doi-asserted-by":"crossref","first-page":"13694","DOI":"10.1128\/JVI.00931-13","article-title":"A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib114","doi-asserted-by":"crossref","first-page":"19953","DOI":"10.1038\/srep19953","article-title":"Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2017.07.001_bib115","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2017.07.001_bib116","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika\u2013dengue virus antibody cross-neutralization","volume":"536","author":"Barba-Spaeth","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.07.001_bib117","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3201\/eid2305.161630","article-title":"Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection","volume":"23","author":"Collins","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib118","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection","volume":"353","author":"Stettler","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.07.001_bib119","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20564","article-title":"Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice","volume":"540","author":"Sapparapu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.07.001_bib120","doi-asserted-by":"crossref","first-page":"14722","DOI":"10.1038\/ncomms14722","article-title":"A human antibody against Zika virus crosslinks the E protein to prevent infection","volume":"8","author":"Hasan","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2017.07.001_bib121","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S1473-3099(16)30471-6","article-title":"Prevention and control of dengue\u2014the light at the end of the tunnel","volume":"17","author":"Pang","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib122","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib123","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib124","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib125","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.07.001_bib126","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.07.001_bib127","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib128","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib130","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1038\/emi.2016.74","article-title":"Vaccines and immunization strategies for dengue prevention","volume":"5","author":"Liu","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.clinthera.2017.07.001_bib131","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2051013613507862","article-title":"Latest developments and future directions in dengue vaccines","volume":"2","author":"Thisyakorn","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.clinthera.2017.07.001_bib132","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull World Heal Organ"},{"key":"10.1016\/j.clinthera.2017.07.001_bib133","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1016\/j.vaccine.2015.11.022","article-title":"Development of a recombinant, chimeric tetravalent dengue vaccine candidate","volume":"33","author":"Osorio","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib134","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib135","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib136","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month-interval dosing study in adults indicates that a single dose of the National Institute of Allergy and Infectious Diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib137","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib138","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/erv.09.139","article-title":"Domain III of the envelope protein as a dengue vaccine target","volume":"9","author":"Guzman","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.clinthera.2017.07.001_bib139","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1016\/j.vaccine.2010.10.004","article-title":"A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice","volume":"28","author":"Block","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib140","doi-asserted-by":"crossref","unstructured":"Valdes I, Marcos E, Suzarte E, et al. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses. Arch Virol. Published online April 9, 2017.","DOI":"10.1007\/s00705-017-3360-y"},{"key":"10.1016\/j.clinthera.2017.07.001_bib141","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2012.03.003","article-title":"Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo","volume":"429","author":"Williams","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.clinthera.2017.07.001_bib142","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","article-title":"The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease","volume":"29","author":"Coller","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib143","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01461-15","article-title":"A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies","volume":"6","author":"Gallichotte","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.clinthera.2017.07.001_bib144","doi-asserted-by":"crossref","first-page":"139ra83","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib145","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib146","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2017.07.001_bib147","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12951-017-0259-4","article-title":"Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice","volume":"15","author":"Versiani","year":"2017","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib148","doi-asserted-by":"crossref","unstructured":"Metz SW, Tian S, Hoekstra G, et al. Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses. Beasley DWC, ed. PLoS Negl Trop Dis. 2016;10:e0005071.","DOI":"10.1371\/journal.pntd.0005071"},{"key":"10.1016\/j.clinthera.2017.07.001_bib149","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein","volume":"18","author":"Raviprakash","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF","volume":"290","author":"Raviprakash","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.clinthera.2017.07.001_bib151","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.vaccine.2005.09.032","article-title":"Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys","volume":"24","author":"Blair","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib152","doi-asserted-by":"crossref","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib153","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0264-410X(94)00059-V","article-title":"Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection","volume":"13","author":"Srivastava","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib154","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molimm.2012.11.007","article-title":"Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM\/E and NS1: their immunity and protective efficacy in mice","volume":"54","author":"Lu","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.virol.2006.08.052","article-title":"DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice","volume":"358","author":"Costa","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.clinthera.2017.07.001_bib156","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1016\/S0264-410X(03)00310-4","article-title":"Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice","volume":"21","author":"Wu","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib157","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/JVI.64.9.4356-4363.1990","article-title":"Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis","volume":"64","author":"Falgout","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib158","doi-asserted-by":"crossref","first-page":"3v11","DOI":"10.1016\/j.jfma.2012.11.006","article-title":"Autoimmunity in dengue pathogenesis","volume":"112","author":"Wan","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.clinthera.2017.07.001_bib159","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1258\/ebm.2011.010339","article-title":"Molecular mimicry between virus and host and its implications for dengue disease pathogenesis","volume":"236","author":"Lin","year":"2011","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib160","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.07.001_bib161","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.07.001_bib162","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models","volume":"23","author":"Shan","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib163","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ebiom.2016.09.028","article-title":"Preventative vaccines for Zika virus outbreak: preliminary evaluation","volume":"13","author":"Kim","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clinthera.2017.07.001_bib164","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2017.07.001_bib165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41598-017-00193-w","article-title":"An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model","volume":"7","author":"Chahal","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2017.07.001_bib166","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coviro.2017.03.006","article-title":"Vaccination strategies against Zika virus","volume":"23","author":"Fernandez","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib167","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2017.07.001_bib168","doi-asserted-by":"crossref","first-page":"jiw638","DOI":"10.1093\/infdis\/jiw638","article-title":"Dengue virus (DENV)-specific antibodies enhance Brazilian Zika virus (ZIKV) infection","volume":"215","author":"Castanha","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib169","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.07.001_bib170","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.amepre.2015.09.006","article-title":"Trials and tribulations on the path to developing a dengue vaccine","volume":"49","author":"Thomas","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib171","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/infdis\/jis749","article-title":"The dengue human challenge model: has the time come to accept this challenge?","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib172","doi-asserted-by":"crossref","unstructured":"Morrison TE, Diamond MS. Animal models of Zika virus infection, pathogenesis, and immunity. Pierson TC, ed. J Virol. 2017;91:e00009\u201317.","DOI":"10.1128\/JVI.00009-17"},{"key":"10.1016\/j.clinthera.2017.07.001_bib173","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.chom.2016.03.010","article-title":"A mouse model of Zika virus pathogenesis","volume":"19","author":"Lazear","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clinthera.2017.07.001_bib174","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.4049\/jimmunol.1101970","article-title":"Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design","volume":"187","author":"Weiskopf","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib175","doi-asserted-by":"crossref","first-page":"17082","DOI":"10.1038\/nmicrobiol.2017.82","article-title":"Host response: cross-fit T cells battle Zika virus","volume":"2","author":"Collins","year":"2017","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib176","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nm.4193","article-title":"Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate","volume":"22","author":"Adams Waldorf","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib177","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2016.05.008","article-title":"Zika virus infection during pregnancy in mice causes placental damage and fetal demise","volume":"165","author":"Miner","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2017.07.001_bib178","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00430-001-0107-9","article-title":"Cross-reactivity in flavivirus serology: new implications of an old finding?","volume":"190","author":"Allwinn","year":"2002","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib179","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/S0124-00642008000200010","article-title":"Dengue-yellow fever sera cross-reactivity; challenges for diagnosis","volume":"10","author":"Houghton-Trivi\u00f1o","year":"2008","journal-title":"Rev salud p\u00fablica (Bogot\u00e1, Colomb"},{"key":"10.1016\/j.clinthera.2017.07.001_bib180","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.aah6187","article-title":"VIROLOGY. Diagnostics for Zika virus on the horizon","volume":"353","author":"Speer","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.07.001_bib181","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2016.2899","article-title":"The emerging Zika virus epidemic in the Americas: research priorities","volume":"315","author":"Lazear","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.07.001_bib182","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3201\/eid1408.080287","article-title":"Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007","volume":"14","author":"Lanciotti","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib183","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMp1607762","article-title":"Considerations for developing a Zika virus vaccine","volume":"375","author":"Marston","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.07.001_bib184","doi-asserted-by":"crossref","unstructured":"Aliota MT, Dudley DM, Newman CM, et al. Heterologous protection against Asian Zika virus challenge in Rhesus macaques. Kashanchi F, ed. PLoS Negl Trop Dis. 2016;10:e0005168.","DOI":"10.1371\/journal.pntd.0005168"},{"key":"10.1016\/j.clinthera.2017.07.001_bib185","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","article-title":"Broadly neutralizing zctivity of Zika virus-immune sera identifies a single viral serotype","volume":"16","author":"Dowd","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2017.07.001_bib186","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fimmu.2014.00093","article-title":"T-cell immunity to infection with dengue virus in humans","volume":"5","author":"Weiskopf","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib187","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1172\/JCI21512","article-title":"Dengue: defining protective versus pathologic immunity","volume":"113","author":"Rothman","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2017.07.001_bib188","doi-asserted-by":"crossref","first-page":"17036","DOI":"10.1038\/nmicrobiol.2017.36","article-title":"Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells","volume":"2","author":"Wen","year":"2017","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.clinthera.2017.07.001_bib189","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chom.2016.12.010","article-title":"Mapping and role of the CD8+ t cell response during primary Zika virus infection in mice","volume":"21","author":"Elong Ngono","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clinthera.2017.07.001_bib190","doi-asserted-by":"crossref","unstructured":"Pardy RD, Rajah MM, Condotta SA, et al. Analysis of the T cell response to Zika virus and identification of a novel CD8+ T cell epitope in immunocompetent mice. Sant AJ, ed. PLOS Pathog. 2017;13:e1006184.","DOI":"10.1371\/journal.ppat.1006184"},{"key":"10.1016\/j.clinthera.2017.07.001_bib191","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(04)16459-3","article-title":"Live flavivirus vaccines: reasons for caution","volume":"363","author":"Seligman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.07.001_bib192","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib193","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clinthera.2017.07.001_bib194","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cell.2016.09.020","article-title":"Zika virus: immunity and vaccine development","volume":"167","author":"Pierson","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2017.07.001_bib195","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.aab4047","article-title":"Public health: dengue vaccines at a crossroad","volume":"350","author":"Wilder-Smith","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.07.001_bib196","first-page":"349","volume":"91","year":"2016","journal-title":"Relev \u00e9pid\u00e9miologique Hebd \/ Sect d\u2019hygi\u00e8ne du Secr\u00e9tariat la Soci\u00e9t\u00e9 des Nations = Wkly Epidemiol Rec \/ Heal Sect Secr Leag Nations"},{"key":"10.1016\/j.clinthera.2017.07.001_bib197","doi-asserted-by":"crossref","first-page":"e0005179","DOI":"10.1371\/journal.pntd.0005179","article-title":"The impact of the newly licensed dengue vaccine in endemic countries","volume":"10","author":"Aguiar","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib198","doi-asserted-by":"crossref","first-page":"15674","DOI":"10.1038\/ncomms15674","article-title":"Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus","volume":"8","author":"Pantoja","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2017.07.001_bib199","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3201\/eid2304.161879","article-title":"Biologic evidence required for Zika disease enhancement by dengue antibodies","volume":"23","author":"Halstead","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2017.07.001_bib200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.15585\/mmwr.mm6512e1","article-title":"Estimating contraceptive needs and increasing access to contraception in response to the Zika virus disease outbreak \u2014 Puerto Rico, 2016","volume":"65","author":"Tepper","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9691","key":"10.1016\/j.clinthera.2017.07.001_bib201","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0140-6736(09)61545-2","article-title":"Abortion ban leads to more maternal deaths in Nicaragua","volume":"374","author":"Moloney","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2017.07.001_bib202","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/jama.2016.2237","article-title":"Pregnancy in the time of Zika","volume":"315","author":"Omer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.07.001_bib203","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1073\/pnas.1704507114","article-title":"Simply put: Vaccination saves lives","volume":"114","author":"Orenstein","year":"2017","journal-title":"Proc Natl Acad Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T11:01:37Z","timestamp":1602586897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817307683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":203,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0149291817307683"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.07.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and Works in Progress: Update on Flavivirus Vaccine Development","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}